CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

Affiliations

• ¹ Department of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
• ² Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA.
• ³ Parnassus Flow Cytometry Core, University of California San Francisco, San Francisco, CA.
• ⁴ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
• ⁵ Department of Pathology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
• ⁶ Center for Cancer Research, National Cancer Institute, Bethesda, MD.
• ⁷ Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH.
• ⁸ Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, University of Washington, Seattle, WA.
• ⁹ Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA.